159 related articles for article (PubMed ID: 28492086)
1. Novel translational therapeutic strategy by sequencing primary liver cancer genomes.
Glantzounis GK; Kyrochristos ID; Ziogas DE; Lykoudis EG; Roukos DH
Future Oncol; 2017 May; 13(12):1049-1052. PubMed ID: 28492086
[No Abstract] [Full Text] [Related]
2. Primary liver cancer genome sequencing: translational implications and challenges.
Ziogas DE; Kyrochristos ID; Glantzounis GK; Christodoulou D; Felekouras E; Roukos DH
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):875-883. PubMed ID: 28712319
[TBL] [Abstract][Full Text] [Related]
3. Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma.
Ziogas DE; Lykoudis EG; Roukos DH; Glantzounis GK
Biomark Med; 2017 Jul; 11(7):515-518. PubMed ID: 28699774
[No Abstract] [Full Text] [Related]
4. Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma.
Lin DC; Mayakonda A; Dinh HQ; Huang P; Lin L; Liu X; Ding LW; Wang J; Berman BP; Song EW; Yin D; Koeffler HP
Cancer Res; 2017 May; 77(9):2255-2265. PubMed ID: 28302680
[TBL] [Abstract][Full Text] [Related]
5. Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.
Villanueva A; Llovet JM
Nat Rev Clin Oncol; 2014 Feb; 11(2):73-4. PubMed ID: 24395088
[No Abstract] [Full Text] [Related]
6. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
7. Building a comprehensive genomic program for hepatocellular carcinoma.
Harring TR; Guiteau JJ; Nguyen NT; Cotton RT; Gingras MC; Wheeler DA; O'Mahony CA; Gibbs RA; Brunicardi FC; Goss JA
World J Surg; 2011 Aug; 35(8):1746-50. PubMed ID: 21225260
[TBL] [Abstract][Full Text] [Related]
8. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacogenomic Landscape in Human Liver Cancers.
Qiu Z; Li H; Zhang Z; Zhu Z; He S; Wang X; Wang P; Qin J; Zhuang L; Wang W; Xie F; Gu Y; Zou K; Li C; Li C; Wang C; Cen J; Chen X; Shu Y; Zhang Z; Sun L; Min L; Fu Y; Huang X; Lv H; Zhou H; Ji Y; Zhang Z; Meng Z; Shi X; Zhang H; Li Y; Hui L
Cancer Cell; 2019 Aug; 36(2):179-193.e11. PubMed ID: 31378681
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma.
Huang CC; Wu MC; Xu GW; Li DZ; Cheng H; Tu ZX; Jiang HQ; Gu JR
J Natl Cancer Inst; 1992 Feb; 84(4):262-4. PubMed ID: 1346405
[No Abstract] [Full Text] [Related]
12. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.
Villanueva A; Toffanin S; Llovet JM
Curr Opin Oncol; 2008 Jul; 20(4):444-53. PubMed ID: 18525342
[TBL] [Abstract][Full Text] [Related]
13. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
Marquardt JU; Galle PR; Teufel A
Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
[TBL] [Abstract][Full Text] [Related]
14. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genome sequencing of the liver cancer genome.
Nakagawa H; Shibata T
Cancer Lett; 2013 Nov; 340(2):234-40. PubMed ID: 23142287
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cells in hepatocellular carcinomas.
Das P; Gupta SD
Indian J Med Res; 2015 Oct; 142(4):362-5. PubMed ID: 26609026
[No Abstract] [Full Text] [Related]
17. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
[TBL] [Abstract][Full Text] [Related]
18. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
19. Molecular bases of the poor response of liver cancer to chemotherapy.
Marin JJG; Briz O; Herraez E; Lozano E; Asensio M; Di Giacomo S; Romero MR; Osorio-Padilla LM; Santos-Llamas AI; Serrano MA; Armengol C; Efferth T; Macias RIR
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):182-192. PubMed ID: 29544679
[TBL] [Abstract][Full Text] [Related]
20. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Lee YS; Kim BH; Kim BC; Shin A; Kim JS; Hong SH; Hwang JA; Lee JA; Nam S; Lee SH; Bhak J; Park JW
Oncotarget; 2015 Jun; 6(18):16449-60. PubMed ID: 25965825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
